Search
Descriptor English: Antineoplastic Agents, Hormonal
Descriptor Spanish: Antineoplásicos Hormonales
Descriptor antineoplásicos hormonales
Scope note: Antineoplásicos que se utilizan para tratar tumores sensibles a hormonas. Los tumores sensibles a hormonas pueden ser tumores que responden a hormonas, tumores que dependen de hormonas o de ambos tipos. Un tumor dependiente de hormonas desaparece cuando se elimina el estímulo hormonal, ya sea mediante cirugía o por bloqueo farmacológico. Los tumores que responden a hormonas pueden desaparecer cuando se administran cantidades farmacológicas de hormonas independientemente de si se observaron previamente signos de sensibilidad hormonal. Entre los principales cánceres que responden a hormonas se encuentran los carcinomas de la mama, próstata y endometrio, los linfomas y ciertas leucemias. (AMA Drug Evaluations Annual 1994, p2079)
Descriptor Portuguese: Antineoplásicos Hormonais
Descriptor French: Antinéoplasiques hormonaux
Entry term(s): Agents, Antineoplastic Hormonal
Antineoplastic Drugs, Hormonal
Antineoplastic Hormonal Agents
Antineoplastic Hormonal Drugs
Antineoplastics, Hormonal
Drugs, Antineoplastic Hormonal
Hormonal Agents, Antineoplastic
Hormonal Antineoplastic Agents
Hormonal Antineoplastic Drugs
Hormonal Antineoplastics
Hormonal Drugs, Antineoplastic
Tree number(s): D27.505.954.248.169
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D018931
Scope note: Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Annotation: consider also NEOPLASMS, HORMONE-DEPENDENT /drug ther
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Previous Indexing: Antineoplastic Agents (1966-1995)
Public MeSH Note: 96
History Note: 96
Entry Version: ANTINEOPL AGENTS HORMONAL
DeCS ID: 32835
Unique ID: D018931
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1996/01/01
Date of Entry: 1995/05/26
Revision Date: 2005/06/30
Antineoplastic Agents, Hormonal - Preferred
Concept UI M0028300
Scope note Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Preferred term Antineoplastic Agents, Hormonal
Entry term(s) Agents, Antineoplastic Hormonal
Antineoplastic Drugs, Hormonal
Antineoplastic Hormonal Agents
Antineoplastic Hormonal Drugs
Antineoplastics, Hormonal
Drugs, Antineoplastic Hormonal
Hormonal Agents, Antineoplastic
Hormonal Antineoplastic Agents
Hormonal Antineoplastic Drugs
Hormonal Antineoplastics
Hormonal Drugs, Antineoplastic



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.


Go to survey